Home/News/May 2013/Cobra Biologics and Vaccibody Sign Agreement to Manufacture DNA Vaccine
Cobra Biologics and Vaccibody Sign Agreement to Manufacture DNA Vaccine
Cobra Biologics Ltd, the international clinical and commercial manufacturer of biologics and pharmaceuticals and Vaccibody AS, a biotechnology company developing the next generation of vaccines against cancer and chronic infections, today announce an agreement to manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies, such as precancerous lesions found in cervical cancer.
Vaccibody’s technology exploits the interplay between tissue, antigen presenting cells (APC), T-cells and B-cells to develop targeted vaccines designed to induce stronger and longer lasting immune responses than traditional vaccines. The platform technology allows for the tailored development of not only enhanced prophylactic vaccines but also therapeutic vaccines against chronic infections and cancers.
Peter Coleman CEO of Cobra Biologics said “Cobra has been manufacturing plasmid therapeutics and DNA vaccines for more than 14 years and I am delighted that we are able to announce the partnership with Vaccibody. Our DNA platform process is based on Cobra’s pioneering heritage in gene therapy manufacturing and technology development that we have successfully used for over 30 customers”.
Ole Henrik Brekke, CEO of Vaccibody said “With the significantly effective preclinical results VB 10.16 has shown, we are delighted now to take the next step towards clinical trials with Cobra Biologics as our manufacturing partner.”